<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Ophthalmol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Ophthalmol</journal-id>
      <journal-title-group>
        <journal-title>BMC Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2415</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24144403</article-id>
      <article-id pub-id-type="pmc">3853479</article-id>
      <article-id pub-id-type="publisher-id">1471-2415-13-60</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2415-13-60</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mature vessel occlusion after anti-VEGF treatment in a retinal arteriovenous malformation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Chuang</surname>
            <given-names>Lan-Hsin</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>lanhsin.chuang@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Wang</surname>
            <given-names>Nan-Kai</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>wang.nankai@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Chen</surname>
            <given-names>Yen-Po</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>yenpo.chen@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Wu</surname>
            <given-names>Wei-Chi</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>weichi666@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A5">
          <name>
            <surname>Lai</surname>
            <given-names>Chi-Chun</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>chichun.lai@gmail.com</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Ophthalmology, Chang-Gung Memorial Hospital, Keelung, Taiwan</aff>
      <aff id="I2"><label>2</label>Department of Ophthalmology, Chang-Gung Memorial Hospital, Linkou, Taiwan</aff>
      <aff id="I3"><label>3</label>Chang Gung University College of Medicine, Taoyuan, Taiwan</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>10</month>
        <year>2013</year>
      </pub-date>
      <volume>13</volume>
      <fpage>60</fpage>
      <lpage>60</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Chuang et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Chuang et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2415/13/60"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>To report engorged vessel occlusion after repeated intravitreal injections of bevacizumab to treat the macular oedema in a case of arteriovenous malformation.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 37-year-old woman presented with a sudden, painless loss of vision in her left eye. Her visual acuity was 20/200 in the left eye, and 20/20 in the right eye. Ophthalmoscopic examination revealed an abnormal tangle of vessels and enlarged draining veins. A fluorescence angiogram revealed fluorescence leakage at a turn near the fovea. Horizontally oriented optical coherence tomography revealed an increased macular thickness and an accumulation of intraretinal fluid, indicating macular oedema. After three intravitreal injections of 1.25&#xA0;mg bevacizumab, her vision improved to 20/20. Ophthalmoscopic examination revealed a decreased calibre of the previously engorged draining veins and ghost vessels. Repeated horizontally oriented optical coherence tomography revealed a decreased macular thickness and the absence of an intraretinal cyst. At the 2-year follow-up visit, the vision of the patient was stable.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This finding implies that certain middle-size vessels can become occluded during anti- vascular endothelium growth factor (anti-VEGF) therapy, which could induce fatal complications if it occurred in the heart or brain. Clinicians should be cautious of the potential thrombotic effects on systemic blood vessels when administering anti-VEGF treatment.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Anti-vascular endothelium growth factor (anti-VEGF) agents have antiangiogenic and oedema-diminishing actions and are used widely to diminish new vessels and reduce the oedema of ocular diseases [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Anti-VEGF is believed to diminish new vessels but not mature vessels and is therefore considered to be a relatively safe therapy [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Herein, we report the first case of a grade 1 retinal arteriovenous (AV) malformation [<xref ref-type="bibr" rid="B5">5</xref>] in which the patient regained vision after repeated intravitreal injections of bevacizumab. Unexpectedly, we observed occlusion of the engorged vessels after repeated intravitreal injections of bevacizumab to treat the macular oedema.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 37-year-old woman presented with a sudden, painless loss of vision in her left eye. Her visual acuity was 20/200 in the left eye and 20/20 in the right eye. Ophthalmoscopic examination revealed an abnormal tangle of vessels and enlarged draining veins (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>A); these signs were compatible with the diagnosis of a grade 1 retinal AV malformation. Fluorescence angiography revealed fluorescence leakage at a turn near the fovea (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>B). Horizontally oriented optical coherence tomography revealed an increased macular thickness and an accumulation of intraretinal fluid, indicating macular oedema (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>C). After three intravitreal injections of 1.25&#xA0;mg bevacizumab, her vision improved to 20/20. Ophthalmoscopic examination revealed a decreased calibre of the previously engorged draining veins and ghost vessels (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>D). Repeated fluorescence angiography failed to show fluorescence leakage (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>E), and horizontally oriented optical coherence tomography revealed a decreased macular thickness and the absence of an intraretinal cyst (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>F). At the 2-year follow-up visit, the vision of the patient was stable.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Fundus photo, fluorescence angiography and optical coherent tomography of patient. (A)</bold>. Ophthalmoscopic examination revealed an abnormal tangle of vessels and enlarged draining veins. <bold>(B)</bold>. Fluorescence angiography revealed fluorescence leakage at a turn near the fovea. <bold>(C)</bold>. Horizontally oriented optical coherence tomography revealed an increased macular thickness and an accumulation of intraretinal fluid, indicating macular oedema. <bold>(D)</bold>. Six months after the third intravitreal injection of bevacizumab, ophthalmoscopic examination revealed a decreased calibre of the previously engorged draining veins and ghost vessels. <bold>(E)</bold>. Fluorescence angiography revealed the absence of leakage at the fovea and a decreased calibre in the occluded arteries. <bold>(F)</bold>. Horizontally oriented optical coherence tomography revealed a decreased macular thickness and the absence of an intraretinal cyst.</p>
        </caption>
        <graphic xlink:href="1471-2415-13-60-1"/>
      </fig>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>In the present case, we chose to use anti-VEGF because we observed fluorescence leakage and retinal oedema during optical coherence tomography. Although the vision of the patient improved to 20/20 and remained stable for 2&#xA0;years after the three intravitreal injections of bevacizumab, the regression of the abnormal, engorged mature vessels after treatment was unexpected. This thromboembolic event can be explained by either spontaneous involution or induced platelet aggregation followed by degranulation and thrombosis through the formation of a complex with VEGF and activation of the platelet Fc&#x3B3;RIIa receptor [<xref ref-type="bibr" rid="B6">6</xref>]. This finding represents the case-report of a single individual and must be studied more extensively before it can be generalised on a larger basis or used to determine a standard of care. However, clinicians should be cautious of the potential thrombotic effects on systemic blood vessels when administering anti-VEGF treatment.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>VEGF: Vascular endothelium growth factor.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests. Chi-Chun Lai is a current consultant of the pharmaceutical corporations Allergan, Bayer, and Novartis. The other authors have no financial disclosures.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>Conceiving and designing the study (CCL, LHC); data collection (NKW, YPC); analysing and interpreting the data (NKW, WCW); writing the manuscript (LHC), providing critical revisions (YPC, WCW) and approving the final version (CCL, LHC, NKW, YPC, WCW). All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2415/13/60/prepub">http://www.biomedcentral.com/1471-2415/13/60/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>Funding was provided through grants CMRPG390271 and CMRPG3A0591 from Chang Gung Memorial Hospital, Linkou, Taiwan.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rajendram</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Fraser-Bell</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kaines</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
          <article-title>A 2-year prospective randomized controlled trial of Intravitreal Bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3</article-title>
          <source>Arch Ophthalmol</source>
          <year>2012</year>
          <volume>130</volume>
          <fpage>972</fpage>
          <lpage>979</lpage>
          <pub-id pub-id-type="doi">10.1001/archophthalmol.2012.393</pub-id>
          <pub-id pub-id-type="pmid">22491395</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Martin</surname>
            <given-names>DF</given-names>
          </name>
          <name>
            <surname>Maguire</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Fine</surname>
            <given-names>SL</given-names>
          </name>
          <etal/>
          <article-title>Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration: two-year results</article-title>
          <source>Ophthalmol</source>
          <year>2012</year>
          <volume>119</volume>
          <fpage>1388</fpage>
          <lpage>1398</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ophtha.2012.03.053</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mintz-Hittner</surname>
            <given-names>HA</given-names>
          </name>
          <name>
            <surname>Kennedy</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Chuang</surname>
            <given-names>AZ</given-names>
          </name>
          <article-title>Efficacy of Intravitreal Bevacizumab for stage 3+ retinopathy of prematurity</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <fpage>603</fpage>
          <lpage>615</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1007374</pub-id>
          <pub-id pub-id-type="pmid">21323540</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Martin</surname>
            <given-names>DF</given-names>
          </name>
          <name>
            <surname>Maguire</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Ying</surname>
            <given-names>GS</given-names>
          </name>
          <etal/>
          <article-title>Ranibizumab and Bevacizumab for neovascular age-related macular degeneration</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <fpage>1897</fpage>
          <lpage>1908</lpage>
          <pub-id pub-id-type="pmid">21526923</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Archer</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Deutman</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ernest</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Krill</surname>
            <given-names>AE</given-names>
          </name>
          <article-title>Arteriovenous communications of the retina</article-title>
          <source>Am J Ophthalmol</source>
          <year>1973</year>
          <volume>75</volume>
          <fpage>224</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">4697179</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Meyer</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Robles-Carrillo</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Robson</surname>
            <given-names>T</given-names>
          </name>
          <etal/>
          <article-title>Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice</article-title>
          <source>J Thromb Haemost</source>
          <year>2009</year>
          <volume>7</volume>
          <fpage>171</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2008.03212.x</pub-id>
          <pub-id pub-id-type="pmid">18983497</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
